tceic.com
>> >>

ppt_

HSCT ? ? ? ? ? 2005.1-2006.6 N=251 255allo-HSCT ? 16264.5% 322 ? 401365 8.4 ? 23372.4% 8927.6% HSCT ? ? ? ? ? 251261 ? 1 ? 184% 100%P0.000 CVC G- CMV to 12 mth -15 0 +30 +60 +90 +120 ? ? CMV ? CMV ? CMV DNA 240ka-pairs) 20 100% HSCT45-86% CMV HSCT21-43% CMV (1999.8-2001.7 (% n=131) () CMV-DNA CMV 69.7% 32.5% 35.1% 34(12-120) 60(21-360) LP Xu et al 2002 CMV 1.0 .9 .8 (1999.8-2001.7 P=0.001 n=131) CMV(86.59%) .7 .6 .5 .4 .3 .2 .1 0.0 0 100 200 300 400 500 600 700 800 CMV(47.31%) LP Xu et al 2002 CMV ? ? ? ? CMV CMV CMV CMV CMV ? ? / ? C C: IgGIgM CPP65 C CMV-DNA CMV-mRNA (wbc,serum,plasma,BAL ) HSCT CMV ? ? ?6/6 ?517 2001408548 HSCT CMV ?URD-BMT ?IV-GVHD ? ?CMV ? ?FOSCARNET 200324631 CMV CMV ? ? / /+WBC ? IVIG CTL CMV CMV ? DHPG -9-2 10mg/kg/d ? +1+30 1mg/kg/d ? ? Pre-emptive therapy DHPG II vs ?CMVvs P<0.05 0/20 vs 5/20 ? 4/20, 3/20, 2/20. 1999208 Pre-emptive therapy CMV LP Xu 2002 CMV-DNA CMV 1.0 Accumulative incidence of CMV disease .9 .8 .7 .6 .5 .4 .3 .2 .1 0.0 0 100 200 300 400 500 P=0.01 More than 2 times ( 47.25%) Once ( 31.26%) Xu LP et al. 2002 never ( 15.56%) 600 700 800 Days after transplantation CMV-DNA,1, >6X102 DHPG or Foscarnet , 75% * DHPG: 5mg/kg q12h q8h * Foscarnet: 60mg/kg CMV PV-PCR n=89) 1.0 CMV .9 .8 .7 .6 .5 .4 .3 .2 .1 0.0 0 P=0.0009 (Breslow) PV-PCR+ (75%) PV-PCR (42.95%) PV-PCR- (30.65%) LP Xu et al 200

:

ppt_.ppt

ppt - (

-1ppt - - .ppt

-1ppt - -1 ?() ? ? ? Transplant-re....

-PPT_.ppt

-PPT - LOGO 1ppt 1. 2. 3. 4. 5. ...

PPT_.ppt

PPT - 1 20

ppt_.ppt

ppt - ...

ppt_.ppt

ppt - (HC)(HSCT) ,...

ppt_.ppt

ppt - ? ? ? ...

PPT_.ppt

PPT - (HC)(HSCT) ,...

IFN-ppt_.ppt

IFN-ppt - IFN- IFN-

ppt_.ppt

ppt___ppt ..., ,, ? ...


PPT_.ppt

PPT - () ()...

̡_.ppt

pany Logo (HSCT)

ppt_.ppt

ppt - ? ...

ppt_.ppt

ppt - ? ? ? ? ? ? ...

[] PPT_.ppt

[] PPT - ? ...

_.pdf

- _ 3 5 C li n

.ppt

___ ...

_.ppt

__...2.(BK

_.ppt

- (HSC

|
All rights reserved Powered by www.tceic.com
copyright ©right 2010-2021
zhit325@126.com